GeoVax Labs, Inc. granted stock options to a senior executive. VP of Business Development John W. Sharkey received an award of 17,600 stock options for common stock on June 17, 2026 at an exercise price of $1.18 per share.
The options vest in three equal annual installments on the first three anniversaries of the grant date and expire on June 17, 2036. This is a compensation-related grant, not an open-market purchase or sale, and leaves Sharkey holding 17,600 options directly after the transaction.
GeoVax Labs CFO Mark Reynolds received a grant of stock options covering 17,600 shares of common stock. The options have an exercise price of $1.18 per share and expire on June 17, 2036. They become exercisable in three equal annual installments on the first three anniversaries of the grant date.
GeoVax Labs, Inc. reported that Chief Scientific Officer Mark J. Newman received a grant of stock options covering 17,600 shares of common stock. The options have an exercise price of $1.18 per share, vest in three equal annual installments starting on the first anniversary of the grant, and expire on June 17, 2036.
GeoVax Labs, Inc. reported that Chief Medical Officer Kelly T. McKee Jr. received a grant of stock options covering 17,600 shares of common stock. The options have an exercise price of $1.18 per share, vest in three equal annual installments starting on the first anniversary of the grant date, and expire on June 17, 2036. Following this award, McKee holds 17,600 stock options directly.
GeoVax Labs, Inc. reported that President and CEO David A. Dodd received a grant of stock options classified as a derivative security. The award covers 29,300 stock options, each exercisable for one share of common stock at an exercise price of $1.18 per share, with no cash paid at grant.
The options expire on June 17, 2036 and become exercisable in three equal annual installments on the first three anniversaries of the grant date. Following this grant, Dodd holds 29,300 stock options directly as reported in this filing, reflecting a routine compensation-related award rather than an open-market purchase or sale.
GeoVax Labs reported results from its annual shareholder meeting. Stockholders elected seven directors, ratified Wipfli LLP as independent auditor for the year ending December 31, 2026, and approved executive compensation on an advisory basis, including holding future say‑on‑pay votes every three years.
As of the April 20, 2026 record date, GeoVax had 2,892,570 shares of common stock outstanding and received proxies for 1,288,684 shares. Shareholders also approved three proposals under Nasdaq listing rules allowing issuance of up to 865,804, 1,269,316 and 1,702,986 shares of common stock upon exercise of previously issued warrants to institutional investors.
Jane Street Group, LLC and affiliates reported beneficial ownership of 292,833 shares of GeoVax Labs common stock as of 06/03/2026. That holding represents 5.6% of the class and is reported as held with shared voting and shared dispositive power.
The filing names subsidiaries Jane Street Capital, LLC (140,064 shares, 2.7%) and Jane Street Global Trading, LLC (152,769 shares, 2.9%) as the relevant holders. Signatures are dated 06/09/2026.
GeoVax Labs, Inc. is registering 7,639,967 shares of common stock for resale by existing investors. These shares are issuable upon exercise of May 2026 inducement and PIPE-related warrants, and the company will not receive any proceeds from resale transactions.
GeoVax may receive cash only if holders exercise the May 2026 warrants, which could generate up to approximately $8.6 million in gross proceeds. Recent financing included a May 2026 warrant exercise inducement yielding about $844,080 in net proceeds and a May 2026 private placement with roughly $2.7 million in net proceeds.
The company is a clinical-stage biotech focused on GEO‑MVA, a Modified Vaccinia Ankara vaccine candidate for mpox and smallpox, with a pivotal Phase 3 trial planned for the second half of 2026, and Gedeptin, an oncolytic gene-directed therapy moving toward Phase 2 in head and neck cancer. GeoVax has no product revenue, reported net losses of approximately $21.5 million in 2025 and $5.3 million for the three months ended March 31, 2026, and has received a going concern opinion, noting existing cash is expected to fund operations only into June 2026.
GeoVax Labs, Inc. entered into a private placement with institutional investors for approximately $3 million in gross proceeds, issuing 2,027,027 pre-funded warrants and 4,054,054 common warrants priced at $1.4799 per pre-funded warrant and accompanying common warrants.
The pre-funded warrants are exercisable immediately at $0.0001/share until fully exercised, while the common warrants, split into Series A and Series B, are exercisable immediately at $1.48/share with five-year and 18‑month terms, respectively. Net proceeds of about $2.7 million are earmarked for working capital and general corporate purposes.
The unregistered securities were issued under Section 4(a)(2) and Rule 506 of Regulation D, with A.G.P./Alliance Global Partners receiving a 7% cash fee plus expense reimbursements as placement agent. Warrant exercises are subject to a beneficial ownership cap of 4.99%, or 9.99% at the holder’s option.